TABLE 2.
Preteens classified as seroresponders to meningococcal group B strains following administration of serogroup B OMV vaccinesa
| Cohort and vaccine | Dose no.b | Type of analysis | No. of participants | No. (%) of seroresponders for indicated strainc
|
|
|---|---|---|---|---|---|
| B:4:P1.7b,4 (NZ98/254) | B:15:P1.7,16 (44/76) | ||||
| A | |||||
| NIPH-MeNZB | 2 | ITT | 221 | 44 (38-50) | 10 (7-15) |
| PP | 217 | 43 (36-50) | 10 (7-15) | ||
| 3 | ITT | 220 | 74 (67-79) | 16 (12-21) | |
| PP | 214 | 73 (67-79) | 16 (12-21) | ||
| MenBvac | 2 | ITT | 54 | 28 (18-41) | 44 (32-58) |
| PP | 53 | 28 (18-42) | 45 (33-59) | ||
| 3 | ITT | 56 | 32 (21-45) | 82 (70-90) | |
| PP | 56 | 32 (21-45) | 82 (70-90) | ||
| B | |||||
| CV-MeNZB | 2 | ITT | 230 | 73 (67-78) | ND |
| PP | 230 | 73 (67-78) | ND | ||
| 3 | ITT | 230 | 79 (73-84) | ND | |
| PP | 217 | 79 (73-84) | ND | ||
| NIPH-MeNZB | 2 | ITT | 55 | 71 (58-81) | ND |
| PP | 55 | 71 (58-81) | ND | ||
| 3 | ITT | 55 | 75 (62-85) | ND | |
| PP | 54 | 76 (63-85) | ND | ||
a
Seroresponders are defined as those showing at least a fourfold increase in serum bactericidal antibody titer compared to the baseline (prevaccination) titer, using interpolated titers. A baseline titer of <1:4 was required to reach a titer of ≥1:8 to be considered a seroresponse.
b
Serum bactericidal antibody titers were measured following administration of the indicated dose.
c
Values in parentheses are 95% confidence intervals. ND, test not performed.